Close Menu

ductal carcinoma in situ

Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.

The company will now be able to market the test, which algorithmically weighs molecular markers and clinical information, in all 50 US states.

Researchers traced clonal populations with shared copy number profiles back to their location in tissue samples, confirming patterns that may have clinical relevance.

With more evidence for clinical utility in the scientific literature, the company expects finalized Medicare coverage before the end of the year.

The firm's revenues were hit by currency translation and differences in the timing of test reimbursement compared with the previous year's quarter.

In a large DCIS cohort, researchers showed the ability of Oncotype DX score to assess recurrence risk in patients treated with breast conservation surgery.

NEW YORK (GenomeWeb) ─ Genomic Health reported after the close of the market Tuesday that its third quarter revenues were up five percent year over year, falling slightly short of the Wall Street consensus estimate.

This article has been corrected to note that Brad Cole is Genomic Health's CFO and COO.

NEW YORK (GenomeWeb News) – Saying that Genomic Health's growth could fall short of consensus expectations, financial services firm Raymond James today downgraded shares of the Redwood City, Calif.-based firm's stock to Underperform from Market Perform.

Pages

Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.

Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.

Slate's Jane Hu compares some at-home genetic tests to astrology.

In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.